西班牙一个由1037名接受生物制剂和JAK抑制剂治疗的风湿病患者组成的队列中重症新型冠状病毒肺炎的发病率。 - Suppr

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.

作者信息

Jovani Vega, Calabuig Irene, Peral-Garrido Maria Luisa, Tovar-Sugrañes Ernesto, López-González María-Del-Carmen, Bernabeu Pilar, Martínez Agustín, Esteve-Vives Joaquim, León-Ramírez Jose-Manuel, Moreno-Perez Oscar, Boix Vicente, Gil Joan, Merino Esperanza, Vela Paloma, Andrés Mariano

机构信息

Reumatología, Hospital General Universitario de Alicante, Alicante, Spain

Reumatología, Hospital General Universitario de Alicante, Alicante, Spain.

出版信息

Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.

DOI:10.1136/annrheumdis-2020-218152

PMID:32586922

Abstract

摘要

相似文献

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.

Ann Rheum Dis. 2022 Jul;81(7):e131. doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.

Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani .

Ann Rheum Dis. 2022 Jul;81(7):e132. doi: 10.1136/annrheumdis-2020-218179. Epub 2020 Jun 25.

What is the true incidence of COVID-19 in patients with rheumatic diseases?

Ann Rheum Dis. 2021 Feb;80(2):e18. doi: 10.1136/annrheumdis-2020-217615. Epub 2020 Apr 22.

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.

The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?

Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i1-i3. doi: 10.1093/rheumatology/key280.

Peri-Arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease A Survey of Practice Trends Among Rheumatologists and Sports Medicine Orthopedic Surgeons.

Bull Hosp Jt Dis (2013). 2024 Sep;82(3):186-193.

JAK inhibitors in rheumatology.

Immunol Med. 2023 Sep;46(3):143-152. doi: 10.1080/25785826.2023.2172808. Epub 2023 Feb 6.

[Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].

Inn Med (Heidelb). 2023 Oct;64(10):1005-1012. doi: 10.1007/s00108-023-01554-6. Epub 2023 Jul 26.

Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.

J Clin Pharm Ther. 2021 Aug;46(4):984-992. doi: 10.1111/jcpt.13380. Epub 2021 Feb 18.

[Biologics and further new drugs for rheumatic diseases since 2000].

Orthopade. 2018 Nov;47(11):906-911. doi: 10.1007/s00132-018-3650-4.

引用本文的文献

COVID-19 Infection and Clinical Outcomes in Hospitalized Patients With Rheumatoid Arthritis: Insights From the National Inpatient Sample.

J Community Hosp Intern Med Perspect. 2024 Jan 12;14(1):5-12. doi: 10.55729/2000-9666.1288. eCollection 2024.

COVID-19 and Pediatric Rheumatology: A Comprehensive Study from a Leading Tertiary Center in Saudi Arabia.

J Epidemiol Glob Health. 2023 Dec;13(4):676-684. doi: 10.1007/s44197-023-00142-z. Epub 2023 Aug 18.

Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2.

Viruses. 2023 Jun 27;15(7):1449. doi: 10.3390/v15071449.

A prospective analysis of the long-term impact of the COVID-19 pandemic on well-being and health care among children with a chronic condition and their families: a study protocol of the KICK-COVID study.

BMC Pediatr. 2023 Mar 22;23(1):130. doi: 10.1186/s12887-023-03912-7.

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.

Lancet Rheumatol. 2021 Oct;3(10):e724-e736. doi: 10.1016/S2665-9913(21)00247-2. Epub 2021 Aug 27.

Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity.

Pharmacol Res. 2021 Nov;173:105848. doi: 10.1016/j.phrs.2021.105848. Epub 2021 Aug 26.

Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany.

RMD Open. 2021 Jul;7(2). doi: 10.1136/rmdopen-2021-001687.

New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.

J Invest Dermatol. 2021 Oct;141(10):2328-2337. doi: 10.1016/j.jid.2021.02.743. Epub 2021 Apr 19.

Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel.

Intern Med J. 2021 May;51(5):682-690. doi: 10.1111/imj.15202. Epub 2021 May 12.

COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.

J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献